GlassScriptPhysician profile
Leonard V Gioia
NPI 1710901558
$1,922.56
in general payments reported to CMS, 2019-2025
22 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $42.01 · 2021: $72.67 · 2022: $277 · 2023: $331 · 2024: $250 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tosoh Bioscience, INC. | $588.00 | 2019 | |
| Abbvie INC. | $430.86 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $193.12 | 2022-2023 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $77.39 | 2022-2023 | Unithroid |
| Corcept Therapeutics | $75.02 | 2023-2024 | Korlym |
| Insulet Corporation | $71.06 | 2019-2024 | Omnipod |
| Medtronic, INC. | $58.67 | 2022-2024 | Minimed 780g |
| Dexcom, INC. | $57.73 | 2025 | Dexcom G6 Transmitter |
| Intuity Medical INC | $42.40 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lilly USA, LLC | $42.19 | 2024-2025 | Zepbound, Mounjaro |
| Ultragenyx Pharmaceutical INC. | $36.57 | 2022-2023 | Crysvita |
| Amgen INC. | $36.42 | 2024 | Tepezza |
| Rgh Enterprises LLC | $35.52 | 2025 | |
| Medtronic Minimed, INC. | $28.07 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.08 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $21.58 | 2023 | Tepezza |
| Nevro Corp. | $21.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.93 | 2019 | |
| Novo Nordisk INC | $18.55 | 2023 | Wegovy |
| Rhythm Pharmaceuticals, INC. | $16.94 | 2025 | Imcivree |
| Ipsen Biopharmaceuticals, INC | $11.80 | 2022 | |
| Clarus Therapeutics INC. | $11.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Gioia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.